$XNCR: Xencor Reports Phase 1 Data for XmAb819 with 45.5% cORR in ccRCC

$XNCR

$XNCR – Xencor Reports Phase 1 Data for XmAb819 with 45.5% cORR in ccRCC

Xencor Inc

2026-10-26 00:00:00 UTC · SEC_8K · All $XNCR

?? Positive AI Sentiment (+6.8 / 10)

Proposed RP3D of 400 mcg/kg showed 45.5% confirmed ORR and 82% 6-month PFS rate.
Disease control rate reached 82% with median PFS not yet reached.
Plans discussions with FDA for potential accelerated approval pathway in 1H 2027.

Observed market reaction after signal

4h +20.69% · Peak +35.94%